Repare Therapeutics reports Q2 2025 revenue $109.5 mln, cash & marketable securities.

• Repare Therapeutics reports Q2 2025 financial results • Entered worldwide licensing agreement with Debiopharm for lunresertib • Evaluating strategic alternatives to maximize shareholder value • Initial data for LIONS and POLAR trials expected in Q4 2025 • $109.5 million in cash and cash equivalents and marketable securities

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, has reported its financial results for the second quarter ended June 30, 2025. The company highlighted its strategic partnerships and the upcoming clinical trial data as key milestones.

Steve Forte, President, Chief Executive Officer, and Chief Financial Officer of Repare, stated, "We remain focused on exploring strategic alternatives and partnerships across our portfolio to enhance long-term shareholder value." The company entered into a worldwide licensing agreement with Debiopharm for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. This agreement includes an upfront payment of $10 million and potential milestone payments up to $257 million, as well as single-digit royalties on global net sales [1].

Repare also announced the out-licensing of its discovery platforms to DCx Biotherapeutics, a Canadian biotechnology company. In connection with this agreement, Repare received a $1 million upfront payment and is eligible for future milestone payments. The company recognized a $5.7 million gain during the quarter from this transaction [1].

The company's cash, cash equivalents, and marketable securities stood at $109.5 million as of June 30, 2025. Revenue from collaboration agreements was $0.3 million for the quarter, compared to $1.1 million and $53.5 million for the same period in 2024. Research and development expenses, net of tax credits, were $14.3 million for the quarter, compared to $30.1 million for the same period in 2024. General and administrative expenses were $6.0 million for the quarter, compared to $8.3 million for the same period in 2024. The company reported a net loss of $16.7 million for the quarter, or $0.39 per share, compared to $34.8 million, or $0.82 per share, for the same period in 2024 [1].

Repare is conducting Phase 1 clinical trials for RP-3467 (POLAR) and RP-1664 (LIONS). Initial data from these trials is expected in the fourth quarter of 2025. The company is also exploring strategic alternatives and partnerships to maximize shareholder value [1].

References:

[1] https://www.marketscreener.com/news/repare-therapeutics-provides-business-update-and-reports-second-quarter-2025-financial-results-ce7c5eddd989f52c